Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study
Background: Aortic stenosis (AS) is the most common primary valvular disease. Currently, there is no pharmacological approach for the medical management of AS. We investigated the effect of osteoporosis therapy with alendronate on hemodynamic progression in patients concurrently affected by AS and o...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Journal of Research in Medical Sciences |
Subjects: | |
Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2020;volume=25;issue=1;spage=65;epage=65;aulast=Alishiri |
id |
doaj-c0cd6e3d68124857aaf38028f140f918 |
---|---|
record_format |
Article |
spelling |
doaj-c0cd6e3d68124857aaf38028f140f9182020-11-25T03:09:14ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362020-01-01251656510.4103/jrms.JRMS_408_20Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective studyGholamhossein AlishiriKiyan Heshmat-GhahdarijaniMohammad HashemiReihaneh ZavarMaryam Moshkani FarahaniBackground: Aortic stenosis (AS) is the most common primary valvular disease. Currently, there is no pharmacological approach for the medical management of AS. We investigated the effect of osteoporosis therapy with alendronate on hemodynamic progression in patients concurrently affected by AS and osteoporosis. Materials and Methods: In this observational prospective study, we enrolled 37 women more than 60 years old with diagnosis of AS and concurrent osteoporosis from August 2017 to December 2019. These patients were treated with alendronate 70 mg every week added to their routine treatment for AS, and their outcomes were compared with 33 patients only affected by AS. Echocardiographic changes and N-terminal-prohormone of brain natriuretic peptide (NT-pro-BNP) level were evaluated during about 2 years of follow-up. Results: The mean follow-up time for the treated and nontreated groups was 20.89 ± 2.73 and 20.84 ± 2.76 months, respectively. Mean gradient (P = 0.02) and peak gradient (P = 0.04) of aortic valve were significantly different between the groups after follow-up. Aortic valve area was decreased 0.09 cm2 in the treated group by alendronate and 0.23 cm2 in the other group (P = 0.001). Furthermore, NT-pro-BNP was significantly decreased in patients treated by alendronate (P = 0.01), but it was increased in nontreated patients (P = 0.04). Conclusion: Treatment with alendronate in patients with AS and concurrent osteoporosis slows down the progression of stenosis and improves their prognosis. This study could open a new pathway for the treatment of AS. Further studies, particularly randomized controlled clinical trial, should be done for providing more evidence.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2020;volume=25;issue=1;spage=65;epage=65;aulast=Alishirialendronateaortic stenosisn-terminal-prohormone of brain natriuretic peptideosteoporosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gholamhossein Alishiri Kiyan Heshmat-Ghahdarijani Mohammad Hashemi Reihaneh Zavar Maryam Moshkani Farahani |
spellingShingle |
Gholamhossein Alishiri Kiyan Heshmat-Ghahdarijani Mohammad Hashemi Reihaneh Zavar Maryam Moshkani Farahani Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study Journal of Research in Medical Sciences alendronate aortic stenosis n-terminal-prohormone of brain natriuretic peptide osteoporosis |
author_facet |
Gholamhossein Alishiri Kiyan Heshmat-Ghahdarijani Mohammad Hashemi Reihaneh Zavar Maryam Moshkani Farahani |
author_sort |
Gholamhossein Alishiri |
title |
Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study |
title_short |
Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study |
title_full |
Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study |
title_fullStr |
Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study |
title_full_unstemmed |
Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study |
title_sort |
alendronate slows down aortic stenosis progression in osteoporotic patients: an observational prospective study |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Research in Medical Sciences |
issn |
1735-1995 1735-7136 |
publishDate |
2020-01-01 |
description |
Background: Aortic stenosis (AS) is the most common primary valvular disease. Currently, there is no pharmacological approach for the medical management of AS. We investigated the effect of osteoporosis therapy with alendronate on hemodynamic progression in patients concurrently affected by AS and osteoporosis. Materials and Methods: In this observational prospective study, we enrolled 37 women more than 60 years old with diagnosis of AS and concurrent osteoporosis from August 2017 to December 2019. These patients were treated with alendronate 70 mg every week added to their routine treatment for AS, and their outcomes were compared with 33 patients only affected by AS. Echocardiographic changes and N-terminal-prohormone of brain natriuretic peptide (NT-pro-BNP) level were evaluated during about 2 years of follow-up. Results: The mean follow-up time for the treated and nontreated groups was 20.89 ± 2.73 and 20.84 ± 2.76 months, respectively. Mean gradient (P = 0.02) and peak gradient (P = 0.04) of aortic valve were significantly different between the groups after follow-up. Aortic valve area was decreased 0.09 cm2 in the treated group by alendronate and 0.23 cm2 in the other group (P = 0.001). Furthermore, NT-pro-BNP was significantly decreased in patients treated by alendronate (P = 0.01), but it was increased in nontreated patients (P = 0.04). Conclusion: Treatment with alendronate in patients with AS and concurrent osteoporosis slows down the progression of stenosis and improves their prognosis. This study could open a new pathway for the treatment of AS. Further studies, particularly randomized controlled clinical trial, should be done for providing more evidence. |
topic |
alendronate aortic stenosis n-terminal-prohormone of brain natriuretic peptide osteoporosis |
url |
http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2020;volume=25;issue=1;spage=65;epage=65;aulast=Alishiri |
work_keys_str_mv |
AT gholamhosseinalishiri alendronateslowsdownaorticstenosisprogressioninosteoporoticpatientsanobservationalprospectivestudy AT kiyanheshmatghahdarijani alendronateslowsdownaorticstenosisprogressioninosteoporoticpatientsanobservationalprospectivestudy AT mohammadhashemi alendronateslowsdownaorticstenosisprogressioninosteoporoticpatientsanobservationalprospectivestudy AT reihanehzavar alendronateslowsdownaorticstenosisprogressioninosteoporoticpatientsanobservationalprospectivestudy AT maryammoshkanifarahani alendronateslowsdownaorticstenosisprogressioninosteoporoticpatientsanobservationalprospectivestudy |
_version_ |
1724663815687110656 |